Two clinical studies, Mare Study (preliminary clinical trial) and Marealis 13TBHM (peer-reviewed, double-blind, placebo-controlled, multicenter clinical trial), were conducted on the bioactive marine peptides (RSPC) in PreCardix® between 2012 and 2015 on over two hundred and twenty male and female participants aged 30 – 75.
Clinical research found that the unique bioactive marine peptides derived from hydrolyzed shrimp shells (Pandalus Borealis) found in PreCardix® have an ACE inhibiting action. The use of bioactive marine peptides in clinical trials resulted in a significant effect on blood pressure health in over 89% of participants within eight weeks or less.
Learn more about the clinical research here.